Cable Hill Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Cable Hill Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-406	Closed	-$427K	–	250
2024 Q3	$427K	Sell	406 -4	-1%	-$4.45K	0.04%	105
2024 Q2	$431K	Buy	+410	New	+$397K	0.05%	101
2023 Q4	–	Sell	-489	Closed	-$402K	–	205
2023 Q3	$402K	Buy	489 +16	+3%	+$12.6K	0.05%	89
2023 Q2	$340K	Sell	473 -88	-16%	-$67.8K	0.04%	116
2023 Q1	$461K	Buy	561 +19	+4%	+$14.3K	0.08%	78
2022 Q4	$391K	Buy	542 +20	+4%	+$14.8K	0.07%	103
2022 Q3	$360K	Buy	522 +70	+15%	+$44.1K	0.07%	89
2022 Q2	$267K	Buy	452 +22	+5%	+$14.3K	0.07%	119
2022 Q1	$300K	Buy	430 +4	+0.9%	+$2.53K	0.2%	89
2021 Q4	$269K	Hold	426	–	–	0.06%	128
2021 Q3	$258K	Buy	426 +6	+1%	+$3.73K	0.06%	117
2021 Q2	$235K	Buy	+420	New	+$213K	0.06%	117
2016 Q4	–	Sell	-13	Closed	-$5K	–	889
2016 Q3	$5K	Buy	+13	New	+$5.21K	﹤0.01%	570

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cable Hill Partners's REGN Position: Q4 2024 in Review

Cable Hill Partners sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 406 shares — an estimated $427K sold.

Cable Hill Partners first reported a position in REGN in Q3 2016 and held it in 13 quarters. The position peaked at $461K in Q1 2023. 1,318 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Cable Hill Partners reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Cable Hill Partners sold 406 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $427K.
Cable Hill Partners first reported a position in Regeneron Pharmaceuticals in Q3 2016 and held it in 13 quarters.
Cable Hill Partners's Regeneron Pharmaceuticals position peaked at $461K in Q1 2023.
1,318 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Cable Hill Partners's 13F filing for Q4 2024, filed 5 Feb 2025.